coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

NLM AIDSLINE Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. Tachedjian G; French M; Mills J; National Centre in HIV Virology
February 28, 1999

Antimicrob Agents Chemother. 1998 Nov;42(11):3038-43. Unique Identifier Human immunodeficiency virus type 1 (HIV-1) isolates obtained from a patient with AIDS were assessed for coresistance to foscarnet and zidovudine. An HIV-1 strain (AP20) coresistant to foscarnet and zidovudine was isolated after 20 months of continuous combination therapy. The reverse transcriptase (RT) gene of AP20 had 41 substitutions which were different from the HXB2-D sequence and 9 that were different from the sequence of its foscarnet-sensitive, zidovudine-resistant progenitor virus (AP6). Six of these mutations were nonpolymorphic (T39A, V108I, K166R, K219R, K223Q, and L228R). Both strains had the conventional mutations mediating zidovudine resistance. In vivo selection may result in HIV-1 strains that are coresistant to foscarnet and zidovudine, but coresistance appears to require a complex evolutionary path and multiple RT mutations. JOURNAL ARTICLE Amino Acid Sequence Anti-HIV Agents/PHARMACOLOGY Drug Resistance Foscarnet/PHARMACOLOGY Human HIV-1/DRUG EFFECTS HIV-1 Reverse Transcriptase/CHEMISTRY/GENETICS Molecular Sequence Data Mutation Polymerase Chain Reaction Support, Non-U.S. Gov't Zidovudine/PHARMACOLOGY

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV No time to lose in the search for an HIV vaccine India Widens Price Control Over Medicines Health group didn't disclose HIV tests, apologizes As Hepatitis C Spreads, Scotland Steps In Russia has 'no anti-AIDS strategy': official Uganda: Over 600 Circumcised in Masaka 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs Antiretroviral regimen associated with less virological failure among HIV-infected children 2012 US medicine sales show shifts by drug type Metro TeenAIDS Honors Booz Allen Hamilton and Abt Associates With Founders Award for a Decade of Investment in DC Youth Study Results from Eunice Kennedy Shriver National Institute of Child Health and Human Development Provide New Insights into HIV/AIDS Monetising Human Waste and 101 (Slightly) Crazy Other Ideas Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases - May 11, 2013 Grand Hotel Bristol, Stresa, Italy New Findings from A.M. Cavalcanti and Colleagues Has Provided New Data on Genetics and HIV/AIDS More than 60 dental patients test positive for viruses U.S. funds multiple vaccine device HAWAII: Reversing Course, Hawaii Lawmakers Open STD Treatment Option to Gays
Information in this article was accurate in February 28, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.